Atara Biotherapeutics (NASDAQ:ATRA) Stock Rating Upgraded by Wall Street Zen

Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Sunday.

A number of other analysts also recently commented on ATRA. Freedom Capital raised shares of Atara Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Weiss Ratings cut shares of Atara Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. Finally, Canaccord Genuity Group set a $13.00 price target on shares of Atara Biotherapeutics and gave the company a “buy” rating in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $9.50.

Atara Biotherapeutics Stock Performance

Shares of NASDAQ ATRA opened at $8.36 on Friday. Atara Biotherapeutics has a one year low of $3.92 and a one year high of $19.15. The firm has a market capitalization of $75.32 million, a P/E ratio of -7.08 and a beta of 0.12. The company’s fifty day moving average is $9.37 and its two-hundred day moving average is $7.33.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.32). The business had revenue of $0.63 million during the quarter, compared to the consensus estimate of $0.55 million. Atara Biotherapeutics had a negative net margin of 269.42% and a negative return on equity of 79.12%. On average, sell-side analysts forecast that Atara Biotherapeutics will post -0.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Quadrature Capital Ltd raised its stake in shares of Atara Biotherapeutics by 22.8% during the 4th quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock worth $368,000 after buying an additional 3,779 shares during the last quarter. Bridgeway Capital Management LLC grew its stake in Atara Biotherapeutics by 133.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 32,691 shares of the biotechnology company’s stock valued at $591,000 after acquiring an additional 18,691 shares during the last quarter. Marshall Wace LLP grew its stake in Atara Biotherapeutics by 28.4% in the 4th quarter. Marshall Wace LLP now owns 148,632 shares of the biotechnology company’s stock valued at $2,689,000 after acquiring an additional 32,836 shares during the last quarter. Walleye Capital LLC acquired a new stake in Atara Biotherapeutics in the 4th quarter valued at about $220,000. Finally, Renaissance Technologies LLC increased its holdings in Atara Biotherapeutics by 58.6% during the 4th quarter. Renaissance Technologies LLC now owns 30,040 shares of the biotechnology company’s stock valued at $543,000 after acquiring an additional 11,104 shares in the last quarter. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.